Thomas Schuetz

1.7k total citations · 1 hit paper
17 papers, 1.2k citations indexed

About

Thomas Schuetz is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Thomas Schuetz has authored 17 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Immunology and 5 papers in Genetics. Recurrent topics in Thomas Schuetz's work include Immunotherapy and Immune Responses (8 papers), Virus-based gene therapy research (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Thomas Schuetz is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Virus-based gene therapy research (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Thomas Schuetz collaborates with scholars based in United States and Belgium. Thomas Schuetz's co-authors include Kelledy Manson, David L. Bilhartz, L. Michael Glodé, Philip W. Kantoff, Dennis Panicali, Wayne R. Godfrey, William L. Dahut, Michael S. Wyand, Jeffrey Schlom and Brent A. Blumenstein and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Thomas Schuetz

16 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

2010 727 citations Philip W. Kantoff, Thomas Schuetz et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Schuetz United States	9	611	609	425	279	190	17	1.2k
Falguni Parikh India	13	747 1.2×	425 0.7×	155 0.4×	474 1.7×	60 0.3×	50	1.3k
Marika Karikoski Finland	17	373 0.6×	491 0.8×	77 0.2×	422 1.5×	79 0.4×	23	1.2k
Sandra Pinton Switzerland	15	405 0.7×	407 0.7×	232 0.5×	685 2.5×	282 1.5×	24	1.3k
Xinming Su United States	15	613 1.0×	615 1.0×	97 0.2×	424 1.5×	83 0.4×	38	1.2k
Ethel R. Pereira United States	13	526 0.9×	282 0.5×	150 0.4×	398 1.4×	41 0.2×	17	1.1k
Kirsi Hämäläinen Finland	17	294 0.5×	211 0.3×	117 0.3×	468 1.7×	66 0.3×	32	1.0k
Lars A. Ormandy Germany	9	1.2k 1.9×	1.8k 3.0×	100 0.2×	329 1.2×	49 0.3×	10	2.3k
Melisa J. Hamilton Canada	13	320 0.5×	692 1.1×	130 0.3×	546 2.0×	57 0.3×	14	1.3k
Ynes Helou United States	10	398 0.7×	536 0.9×	66 0.2×	347 1.2×	55 0.3×	11	1.1k
Anandi Sawant United States	15	489 0.8×	476 0.8×	159 0.4×	317 1.1×	22 0.1×	22	948

Countries citing papers authored by Thomas Schuetz

Since Specialization

Citations

This map shows the geographic impact of Thomas Schuetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Schuetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Schuetz more than expected).

Fields of papers citing papers by Thomas Schuetz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Schuetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Schuetz. The network helps show where Thomas Schuetz may publish in the future.

Co-authorship network of co-authors of Thomas Schuetz

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Schuetz. A scholar is included among the top collaborators of Thomas Schuetz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Schuetz. Thomas Schuetz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Albu, Diana I., Tristan Lubinski, Jason Kong, et al.. (2025). Abstract 7297: Enhanced efficacy of CTX-471, a CD137 agonist antibody, in models of immune checkpoint failure via simultaneous blockade of neo-angiogenesis. Cancer Research. 85(8_Supplement_1). 7297–7297.

Barve, Minal, et al.. (2024). Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.. Journal of Clinical Oncology. 42(16_suppl). 2535–2535. 1 indexed citations

Albu, Diana I., Benjamin Wolf, Yan Qin, et al.. (2024). A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity. OncoImmunology. 13(1). 2316945–2316945. 2 indexed citations

Pilgrim, Sarah, et al.. (2023). Trial in progress: A phase 2 study of CTX-009 in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens.. Journal of Clinical Oncology. 41(4_suppl). TPS281–TPS281. 1 indexed citations

You, Weon‐Kyoo, et al.. (2022). Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development. Molecular Cancer Therapeutics. 22(1). 3–11. 37 indexed citations

Draghi, Monia, Jamie L. Schafer, Allison Nelson, et al.. (2019). Abstract 4972: Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma. Cancer Research. 79(13_Supplement). 4972–4972. 10 indexed citations

Monteith, David, Emily C. Collins, Corinne Vandermeulen, et al.. (2017). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers. Frontiers in Pharmacology. 8. 740–740. 54 indexed citations

Kantoff, Philip W., Thomas Schuetz, Brent A. Blumenstein, et al.. (2010). Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 28(7). 1099–1105. 727 indexed citations breakdown →

Godfrey, Wayne R., Brent A. Blumenstein, Thomas Schuetz, et al.. (2009). 7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). European Journal of Cancer Supplements. 7(2). 406–406. 2 indexed citations

10.

Plante, Mark, Howard L. Kaufman, Ron Israeli, et al.. (2006). A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer. Journal of Translational Medicine. 4(1). 1–1. 153 indexed citations

11.

Muenzer, Joseph, Müge Güçsavaş‐Çalıkoğlu, Shawn E. McCandless, Thomas Schuetz, & Alan Kimura. (2006). A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Molecular Genetics and Metabolism. 90(3). 329–337. 180 indexed citations

12.

Manson, Kelledy, et al.. (2006). A novel non-HLA-restricted cellular immune assay for monitoring patient (pt) response to targeted immunotherapeutics. Journal of Clinical Oncology. 24(18_suppl). 2567–2567. 1 indexed citations

13.

Kantoff, Philip W., et al.. (2006). Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology. 24(18_suppl). 2501–2501. 23 indexed citations

14.

Schuetz, Thomas, Howard L. Kaufman, J. L. Marshall, & Howard Safran. (2005). Extended survival in second-line pancreatic cancer after therapeutic vaccination. Journal of Clinical Oncology. 23(16_suppl). 2576–2576. 14 indexed citations

15.

Kaufman, Howard L., Rosanna Di Paola, Margaret von Mehren, et al.. (2004). Safety profile of therapeutic pox virus-based vaccines for cancer. Journal of Clinical Oncology. 22(14_suppl). 2513–2513. 1 indexed citations

16.

Schuetz, Thomas, John Marshall, Howard L. Kaufman, Howard Safran, & Dennis Panicali. (2004). Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer. Journal of Clinical Oncology. 22(14_suppl). 2564–2564. 9 indexed citations

17.

DeRaffele, Gail, Josephine Mitcham, Dorota Moroziewicz, et al.. (2004). Manipulating the local tumor microenvironment with vaccinia virus expressing costimulatory molecules for the treatment of melanoma. Journal of Clinical Oncology. 22(14_suppl). 7504–7504. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact